Together we make a mark in business and society; bringing digital transformation to life.
Annual Report 2020
NNIT A/S, Oestmarken 3A, DK-2860 Soeborg • CVR no. 21 09 31 06 M Contents
2 Annual Report 2020
Table of Management's Review Financial Statements 2020 Contents The Bigger Picture Statements NNIT Group at a Glance 4 Management’s Statement 52 Chairman & CEO letter 5 Independent Auditor’s Report 53 Main Highlights 2020 8 2020 Financial Performance 9 Consolidated Financial Five-year Performance Highlights 12 Statements Commercial Highlights 2020 13 Income Statement and Statement Outlook 15 of Comprehensive Income 57 Excellis Health Solutions 16 Balance Sheet 58 Statement of Cash Flows 59 Our Business Statement of Changes in Equity 60 Notes 62 Market Trends 18 Business Model 19 The Industries and Customers We Serve 20 Parent Company Financial Statements NNIT Group Overview 21 Strategy 22 Income Statement 99 Our People 25 Balance Sheet 100 Our Responsibility 30 Statement of Changes in Equity 101 Update on ESG 33 Notes 103 Customer Experience at the Core 34 Equity Story 35 Insights from the Digital Engine Rooms 36
Governance Corporate Governance 38 Risk Management 41 Remuneration 44 Shareholder Information 45 Board of Directors 47 Group Management 50 M The bigger picture
3 Annual Report 2020 Management's Review
The Bigger Picture NNIT Group at a Glance 4 Chairman & CEO letter 5 The Bigger Main Highlights 2020 8 2020 Financial Performance 9 Five-year Performance Highlights 12 Commercial Highlights 2020 13 Picture Outlook 15 Excellis Health Solutions 16 M At a glance
4 Annual Report 2020 Management's Review
NNIT Group at a Glance
NNIT is a leading provider of IT transformation services At NNIT, we believe that we can make a mark in business and society and solutions to international life sciences companies together with our customers and and for the Danish private and public sector. partners. Standing firmly on our three core values, this is the NNIT way:
Aspiration Together we make a mark in business and society; bringing digital transformation to life.
Strategy We provide Winning Solutions based on Proven Concepts delivered Fit for Purpose and First Time Right.
Headquartered in Denmark, the NNIT Group has companies and subsidiaries throughout Europe, Group Companies: North America and Asia. Values Open and honest Conscience driven Value adding An NNIT Group Company An NNIT Group Company M Letter from management
5 Annual Report 2020 Management's Review
Resilience in a Year of Transformation and a Global Pandemic
2020 was seen as a year of transformation, dedicated Focus on our strategy On November 9, we announced the acquisi- Throughout the year, the organization was tion of Excellis Health Solutions, delivering to executing on our revised strategy. Our guidance was heavily invested in bringing our strategy and on our 2022 strategy to broaden our capa- set accordingly, and we succeeded in delivering on our Winning Solutions to the market. This came bilities within the international life sciences to fruition with new wins as well as exten- business via M&A. In Excellis, we saw a great promise despite business impact from the COVID-19 sions of existing contracts. business and cultural match from the begin- pandemic causing insecurity and delay in decisions and ning, and we expect that we will achieve an overall slowdown in the market. We also continued to execute on the pre- synergies from cross-selling and the mutual announced cost restructuring program international expansion – not least through by introducing automation initiatives and the added offering of supply chain manage- reducing both employees and administrative ment services brought to the NNIT Group via Growth in Life Sciences and continued decrease of 7.5%, gross profit margin of 14% costs according to plan. Excellis. strong financial position and an operating profit margin before spe- We made great headway within the Life Sci- cial items of 5.8%. Not exactly satisfactory, The cost restructuring program supported Continuing to make our mark in ences business unit, achieving an impressive but in line with expectations, nevertheless. a margin improvement in the Life Sciences business and society annual growth rate of 26% and 14% for Life International, Life Sciences Denmark and We believe in our strategy, we believe in our Sciences International and Life Sciences In addition, due to the underlying cash flow Private & Public segments. However, as Winning Solutions – and we believe that we Denmark, respectively. generation and the strong financial position expected, it was not able to fully compen- can help bring digital transformation to life, of NNIT, in August, we were able to maintain sate for the loss of business from the Novo to the benefit of our customers and society As expected, the effects from the loss of two payment of an interim dividend for 2020 of Nordisk Group. in general. Digital transformation is more major contracts impacted the 2020 financial DKK 2.00 per share, corresponding to DKK important than ever and, in 2020, we saw performance resulting in a Group revenue 49 million. this particularly through great traction within 6 Annual Report 2020 Management's Review
our solutions Veeva Powerhouse for Life Sci- especially with our customers. This is a big ences customers, D365 Solutions and Hybrid part of the NNIT culture. Cloud. In addition, NNIT has a strong conscience. Together with our customers, we aim to In 2020, we continued to focus on corporate continue to develop our solutions and ser- responsibility in general, including UN Sus- vices, adding value by improving quality and tainable Development Goals (SDG), rolling productivity – and to keep vital infrastructure out various initiatives that we will continue in systems up and running. 2021. Our UN SDG focus includes:
Corporate Responsibility and safeguard- • SDG 4: Quality Education ing the NNIT culture • SDG 5: Gender Equality With many people working from home for • SDG 9: Industry, Innovation and extended periods of time throughout the Infrastructure year and most on-site events cancelled, • SDG 12: Responsible Consumption safeguarding the NNIT culture was and is a and Production challenge. For many years, we have had clear policies Technically, we were able to work from on Corporate Responsibility, Inclusion and home from day one of the first lock-down, Diversity, stating a zero-tolerance approach and we assisted many of our customers in to any type of discrimination. The increased successfully making the transition to mostly focus on gender inequality and sexism in working online. Even so, working remotely 2020 prompted us to revisit and re-promote is not the same as physically being there, these policies together with our Whistle- and we are looking forward to returning to blower program. We will continue to do so normal and being able to meet in person, in 2021.
CARSTEN DILLING, CHAIRMAN OF THE BOARD 7 Annual Report 2020 Management's Review
Our transitional journey continues are tough. We appreciate the enormous ef- While 2020 was a difficult year and a year fort our employees put in daily and we want of transition, we strongly believe that our to take this opportunity to reassure them strategy and our talented people will help that it makes a difference, which we believe us through the challenges we face. We will manifest as soon as 2021. We would also expect that the numbers will show growth like to extend a big thank you to our existing and improved profitability in 2021. We will customers and a big welcome to our new achieve this growth both organically and customers, who we are looking forward to inorganically, and we remian on the lookout advising and supporting in 2021 and beyond. internationally for attractive M&As within life sciences, as well as in Denmark within our Thank you for your continued trust and Winning Solutions areas. dedication.
As always, we owe a huge thank you to our Let’s make a mark together in 2021. employees who continue to fight to promote our business and workplace with the highest Carsten Dilling, Chairman of the Board level of professionalism every day. This, of Per Kogut, CEO course, is all the more difficult when times
PER KOGUT, CEO M Main highlights
8 Annual Report 2020 Management's Review
Main Highlights 2020
Growth in Life Sciences international Operating profit margin Financial strength Free cash flow Before special items Net debt to EBITDA ratio DKK million
26 % 5.8 % 1.2 143
Revenue Dividend payout Average number of full-time DKK million DKK million employees 3,007 3,058 3,237 2,765 2,851 2,830 3,129 3,083
2,937
2,677
2016 2017 2018 2019 2020 2020 dividend74 payouts corresponds 2016 2017 2018 2019 2020 to a dividends yield of 2.5% M Financial performance
9 Annual Report 2020 Management's Review
2020 Financial Performance
Revenue decrease of 7.5% to DKK 2,830 million and an operating profit margin before special items of 5.8% in 2020.
NNIT concluded 2020 in-line with the finan- Novo Nordisk Group increased to 74% in Business and cost restructuring plan involvement, while both staff- and external cial guidance with revenue growth of -7.5% 2020 from 69% in 2019. The business and cost restructuring plan has costs have been reduced. Compared to to DKK 2,830 million and an operating profit progressed in line with expectations during 2019 utilization has increased. Measures margin before special items of 5.8%. Gross profit, costs and operating profit 2020. Automation initiatives have secured to further optimize the business, herunder In 2020 gross profit decreased by 19% to a more efficient operation with less manual utilization, are constantly put in place. CAPEX investments of DKK 135 million DKK 387 million leading to a gross profit corresponding to 4.8% of revenue were in margin of 14% compared to 16% in 2019. the low end of the outlook for 2020. Gross profit was mainly impacted by the loss of business with the Novo Nordisk Group Income statement Revenue development which could not be offset fully by the cost Life Sciences international and Life Sciences restructuring plan. DKK million 2020 2019 Change
Denmark continued the strong growth in Revenue 2,830 3,058 -7.5% 2020 with revenue increasing 26% and 14% Sales and marketing costs decreased by 3.1% Cost of goods sold 2,443 2,583 -5.4% respectivly. Despite the strong growth in and administrative expenses decreased by Gross profit 387 475 -18.5% Life Sciences, total revenue declined by 7.5% 9.5% in 2020 due to staff reductions as part Gross profit margin 13.7% 15.5% -1.8pp mainly due to the expected decline stem- of the cost restructuring plan. Sales and marketing costs 127 131 -3.1% ming from the loss of the large application Administrative expenses 95 105 -9.5% maintenance agreement and the renewed In 2020, operating profit before special items Operating profit before special items* 165 239 -31.0% operation maintenance agreement with the ended at DKK 165 million. This corresponds Operating profit margin before special items* 5.8% 7.8% -2.0pp Novo Nordisk Group. Further, the phasing to an operating profit margin before special Special items* 43 24 79.2% out of the Pandora contract in Private & Pub- items of 5.8% in 2020 compared to 7.8% in Operating profit 122 215 -43.3% Operating profit margin 4.3% 7.0% -2.7pp lic impacted revenue from Q3 2020. 2019. Net financials -20 16 -225.0% Profit before tax 102 231 -55.8% As a consequence of the declining business Special items amounted to DKK 43 million Tax 26 48 -45.8% with the Novo Nordisk Group the share of and mainly related to severance payments Effective tax rate 25.5% 20.8% 4.7pp NNIT’s revenue from customers outside the to terminated employees as a consequence Net profit 76 183 -58.5% of restructurings. * Special items comprise costs that cannot be attributed directly to NNIT's ordinary activities and are non-recurring of nature 10 Annual Report 2020 Management's Review
Net financials and tax Life Sciences Denmark Enterprise Public Net financials showed an expense of DKK Revenue from customers in Life Sciences Revenue from Enterprise customers de- Revenue from Public customers increased 20 million in 2020 compared to an income Denmark increased by 14% in 2020 mainly creased by 11% driven by the phasing out by 3.8% mainly due to additional business of DKK 16 million in 2019. The negative de- due to higher activity with existing custom- of the Pandora contract which could not be with existing customers. velopment was primarily due to adjustment ers and business with the new customer fully offset by business from new customers of the Valiance earn-out agreement and Orifarm. like Radius and Saint-Gobain. decrease in gains from hedge instruments. Novo Nordisk Group In 2020, income tax decreased to DKK 26 Revenue from the Novo Nordisk Group de- million compared to DKK 48 million in 2019 clined by DKK 223 million or 23% in 2020, pri- mainly due to the lower operating profit. The marily due to the loss of the large application effective tax rate for 2020 was 25.5%, an in- maintenance agreement and the renewed Business units crease of 4.7pp compared to 2019 due to an operation maintenance agreement which increase in permanent differences regard- both impacts the revenue and profitability. Life Sciences ing special items as well as non-deductable DKK million 2020 2019 2019-2020 withholding tax regarding dividend received The decline in business with the Novo Nord- from subsidiaries. isk Group had a significant negative impact Novo Nordisk Group 732 955 -23.4% on the business units gross profit, operating Life Sciences international 456 361 26.3% Life Sciences, revenue and profit and corresponding margins. Operating Life Sciences Denmark 261 230 13.5% Life Sciences revenue 1,449 1,546 -6.3% profitability review profit before special items in Life Sciences Revenue from Life Sciences decreased by decreased by 40% to DKK 122 million leading Operating profit before special items 122 203 -39.9% 6.3% in 2020. Revenue from Life Sciences to an operating profit margin of 8.4% com- Operating profit margin before special items 8.4% 13.1% -4.7pp international and Life Sciences Denmark pared to 13% in 2019. showed strong growth but could not fully Private & Public offset the decline in revenue from the Novo Private & Public, revenue and DKK million 2019 2019-2020 Nordisk Group. profitability review 2020
Revenue in the Private & Public segment Enterprise 712 802 -11.2% Life Sciences international decreased by 8.7% in 2020 due to decreas- Public 407 392 3.8% Revenue from Life Sciences international ing activities in the Enterprise and Finance Finance 262 318 -17.6% increased by 26% in 2020. The growth was segments. Further, the COVID-19 situation Private & Public revenue 1,381 1,512 -8.7% driven by Veeva related projects, Production impacted the performance due to the ongo- IT (Manufacturing Execution System) and by ing uncertainty leading to delays of tenders Operating profit before special items 43 36 19.4% Operating profit margin before special items 3.1% 2.4% 0.7pp the acquisition of Excellis. and projects. 11 Annual Report 2020 Management's Review
Finance Free cash flow The decrease was mainly due to payment the backlog. Corrected for that, the underly- Revenue from Finance customers decreased The free cash flow for 2020 was DKK 143 of dividends and a negative change in cash ing backlog has increased around 1.5% in by 18% mainly due lower project revenue million compared to a free cash flow of flow hedges and exchange rate adjustments the beginning of Q1 2021 compared to Q1 from existing customers and the expiry of DKK 242 million in 2019. The decrease was related to sudisdiaries. 2020. the contract with Alka (acquired by Tryg). mainly driven by the acquisition of Excellis and lower net profit, partly countered by Order entry backlog The backlog from Life Sciences custom- Operating profit before special items in postponement of payment of VAT amount- At the beginning of Q1 2021, NNIT’s order ers excluding the Novo Nordisk Group Private & Public increased by 19% to DKK 43 ing to approx. DKK 100 million. entry backlog for 2021 amounted to DKK increased by 38% driven by Life Sciences million leading to an operating profit margin 1,999 million, which was a decrease of 2.0% international and the acquisition of Excellis, before special items of 3.1%. The margin NNIT paid ordinary dividends of DKK 49 mil- compared to last year. while the Novo Nordisk Group declined by increase is mainly driven by the cost restruc- lion in March 2020 and interim dividends of 22% (decline of 11% corrected for the price turing program. DKK 49 million in August 2020. At the same time last year, the considerable reduction on the prolonged operation main- price reduction on the prolonged operation tenance agreement). Balance sheet maintenance agreement with the Novo Nor- At December 31, 2020 total assets was DKK disk Group was not known and included in Private & Public decreased by 4.5% mainly 2,662 million which is an increase of DKK 49 due to expiry of the Pandora outsourcing million compared to December 31, 2019 The contract and delayed order intake as a result increase was primarily due to an increase of the COVID-19 situation. in intangible assets due to the acquisition Operating profit and margin Order entry backlog of Excellis partly countered by a decrease in The high growth in NNIT’s project business before special items lease assets and trade receivables. DKK million with low backlog visibility and a declining/ DKK million % stagnating multiyear outsourcing business 0 2 At December 31, 2020, net cash and cash 2 00 makes the backlog numbers less useful as 2 0 equivalents amounted to DKK -161 million a predictor for revenue growth. Therefore, 00 0 which is a decrease of DKK 52 million com- 2 000 the backlog for the current year should be 2 0 pared to December 31, 2019. The decrease 00 interpreted with caution. 200 was mainly driven by the acquisition of Excellis (DKK 188 million) and payment of 000 Events after the balance sheet date 0 earn-out (DKK 62 million), partly countered There have been no events after the balance 00 00 2 by cash flows from operating activities. sheet date which would have a significant